Abstract
Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily x 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyotype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exc...Continue Reading
References
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Oct 1, 1989·European Journal of Haematology·A M CarellaE Damasio
Jun 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M AbromowitchG Rivera
Jul 15, 1984·Cancer·J KrischerL S Frankel
Jan 1, 1996·Leukemia & Lymphoma·J J MazzaP A Cassileth
Mar 1, 1997·British Journal of Haematology·L M Secker-WalkerG Harrison
Feb 1, 1997·Annals of Hematology·V NüsslerW Wilmanns
Jan 1, 1997·Journal of Pediatric Hematology/oncology·M L BernsteinG R Buchanan
May 7, 1998·Leukemia & Lymphoma·R BassanT Barbui
Aug 27, 1998·The New England Journal of Medicine·H CavéE Vilmer
Jul 29, 2000·Leukemia·M A Belaud-RotureauF Belloc
Sep 20, 2000·Klinische Pädiatrie·U CreutzigM Zimmermann
Dec 2, 2000·Annals of Hematology·M FlasshoveM E Scheulen
Mar 10, 2001·Leukemia·U CreutzigA Feldges
May 9, 2001·American Journal of Hematology·S BaroneM Wetzler
Nov 9, 2001·Leukemia & Lymphoma·F HartmannM Pfreundschuh
Jan 5, 2002·American Journal of Hematology·S T LeeY H Min
Sep 5, 2002·Cancer·Mark A WeissTodd E Roma
Dec 24, 2002·Cancer Chemotherapy and Pharmacology·Yesid AlvaradoFrancis J Giles
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francis J GilesHagop M Kantarjian
Jun 5, 2003·British Journal of Haematology·Maria Ilaria Del PrincipeSergio Amadori
Citations
Jan 27, 2007·Cancer Chemotherapy and Pharmacology·Alessandra TedeschiEnrica Morra
Oct 1, 2011·Current Treatment Options in Oncology·Peter H Wiernik
Dec 6, 2012·Journal of Pediatric Hematology/oncology·Michael J JoyceBruce Camitta
Dec 6, 2008·Neurosurgery·Neal LutherMark M Souweidane
Feb 4, 2010·International Journal of Molecular Medicine·Andrew DavenportQ Ping Dou
Jul 12, 2008·Hematology·Merat Karbasian-EsfahaniLool Abebe
Nov 21, 2013·Leukemia & Lymphoma·Shira DinnerMichaela Liedtke
Nov 1, 2006·Expert Opinion on Drug Discovery·Janos Nadas, Duxin Sun
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Peter H Wiernik
Dec 3, 2014·Leukemia Research·Michaela LiedtkeBruno Medeiros